Full Press Release Details
Disclaimer All statements contained herein other than statements
of historical fact, including statements regarding our future results of operations and financial position, our business strategy
and plans, and our objectives for future operations, are forward-looking statements. The words "believe," "may,"
"will," "estimate," "continue," "anticipate," "intend," "expect,"
and similar expressions are intended to identify forward looking statements. We have based these forward-looking statements largely
on our current expectations and projections about future events and trends that we believe may affect our financial condition,
results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These
forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the "Risk
Factors" section of the registration statement on Form S-1 we filed on April 27, 2016. Moreover, we operate in a very competitive
and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks,
nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may
cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these
risks, uncertainties and assumptions, the future events and trends discussed in this presentation may not occur and actual results
could differ materially and adversely from those anticipated or implied in the forward looking statements.
We built Moleculin around a diverse portfolio of disruptive cancer
technologies, each with high revenue potential. Our lead leukemia drug candidate has already shown life-saving potential in clinical
trials. We have a unique compound that appears to both attack the most difficult cancers directly while also stimulating the patient's
natural immune response and we have a promising new approach to reaching and treating brain tumors. - Wally Klemp, Chairman
Veteran Management Team Cisplatin Carboplatin COO Harvard, Tufts,
UVA Dana Farber, FDA #1 INC 500 List $400 million in revenue CMO CEO
Advisors and Board Members Reata Pharmaceuticals Big 4 audit partners
Multi-billion dollar exit Cancer experts
All of our technologies were developed at MD Anderson Cancer Center,
the world's largest cancer research facility headquartered within the world's largest medical center With over 1,500
cancer researchers, our sponsored research has been supported by truly state of the art resources
Technology Portfolio
Discovery (Finding potential new drugs) Pre-Clinical Development
(Laboratory Testing) IND Filing (Investigational New Drug; FDA Filing) Phase I/II (Human safety & proof of concept) Approval
Trial (Phase IIb or III as required) Adult AML WP1066 (Glioblastoma, metastatic melanoma) WP1122 (Glioblastoma) Pediatric acute
leukemia WP1220 (CTCL) WP1066 (Pancreatic, other) (To be refiled) Annamycin WP1066 Portfolio WP1122 Portfolio = Potential key
value inflection point Sponsored CNS malignancies Research
BMT (Results in Cure) 20% 80% Success Failure Induc4on Therapy
(Qualify for BMT) 80% 20% Success Failure
Non-cardiotoxic Avoids multidrug resistance More potent Cardiotoxic
Defeated by multidrug resistance Current Drugs Annamycin
Annamycin Delivers Relapsed/Refractory Acute Leukemia Patients
50% Efficacy Signal 30% Cleared Bone Marrow Blasts Annamycin gives new hope to patients who have run out of options Patients failed
an average of 5 previous Induction Therapy attempts with standard of care
Annamycin (based on last trial) What is possible if we get to
WP1066 Directly attacks the worst cancers Recruits natural immune
system IRB approved for human trial
WP1122 Cuts off fuel supply to brain tumors Outperforms billion-dollar
drug Human trials in 1-2 years
Investment Highlights Multiple shots Worldclass collaboration
Game-changing breakthroughs Solid protection Veteran management